A deeper understanding of the interaction between <i>CHD1</i> loss and PARP inhibitor sensitivity will be needed to determine the optimal use of targeted agents such as talazoparib in the context of castration resistant prostate cancer. Here, CHD1 is linked to prostate cancer.